190 related articles for article (PubMed ID: 28027687)
21. The role of ASXL1 in hematopoiesis and myeloid malignancies.
Asada S; Fujino T; Goyama S; Kitamura T
Cell Mol Life Sci; 2019 Jul; 76(13):2511-2523. PubMed ID: 30927018
[TBL] [Abstract][Full Text] [Related]
22. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.
Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Peng J; Tang G; Goswami M; Young KH; Singh R; Medeiros LJ; Kantarjian HM; Luthra R; Wang SA
J Hematol Oncol; 2015 May; 8():45. PubMed ID: 25952993
[TBL] [Abstract][Full Text] [Related]
23. The ASXL1-G643W variant accelerates the development of CEBPA mutant acute myeloid leukemia.
D'Altri T; Wilhelmson AS; Schuster MB; Wenzel A; Kalvisa A; Pundhir S; Meldgaard Hansen A; Porse BT
Haematologica; 2021 Apr; 106(4):1000-1007. PubMed ID: 32381577
[TBL] [Abstract][Full Text] [Related]
24. Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations.
Chou WC; Huang HH; Hou HA; Chen CY; Tang JL; Yao M; Tsay W; Ko BS; Wu SJ; Huang SY; Hsu SC; Chen YC; Huang YN; Chang YC; Lee FY; Liu MC; Liu CW; Tseng MH; Huang CF; Tien HF
Blood; 2010 Nov; 116(20):4086-94. PubMed ID: 20693432
[TBL] [Abstract][Full Text] [Related]
25. Co-mutation of
Song J; Moscinski L; Yang E; Shao H; Hussaini M; Zhang H
In Vivo; 2023; 37(3):985-993. PubMed ID: 37103105
[TBL] [Abstract][Full Text] [Related]
26. ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events.
Haferlach C; Bacher U; Schnittger S; Alpermann T; Zenger M; Kern W; Haferlach T
Genes Chromosomes Cancer; 2012 Apr; 51(4):328-37. PubMed ID: 22162288
[TBL] [Abstract][Full Text] [Related]
27. TET2, ASXL1 and EZH2 mutations in Chinese with myelodysplastic syndromes.
Wang J; Ai X; Gale RP; Xu Z; Qin T; Fang L; Zhang H; Pan L; Hu N; Zhang Y; Xiao Z
Leuk Res; 2013 Mar; 37(3):305-11. PubMed ID: 23099237
[TBL] [Abstract][Full Text] [Related]
28. [Clinical Characteristics and Prognosis of Acute Myeloid Leukemia Patients with ASXL1 Gene Mutation].
Zhou NC; Li GH; Qin WW; Wang WQ; Guo HP; Liu C; Liu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Dec; 29(6):1741-1745. PubMed ID: 34893103
[TBL] [Abstract][Full Text] [Related]
29. Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation.
Nagase R; Inoue D; Pastore A; Fujino T; Hou HA; Yamasaki N; Goyama S; Saika M; Kanai A; Sera Y; Horikawa S; Ota Y; Asada S; Hayashi Y; Kawabata KC; Takeda R; Tien HF; Honda H; Abdel-Wahab O; Kitamura T
J Exp Med; 2018 Jun; 215(6):1729-1747. PubMed ID: 29643185
[No Abstract] [Full Text] [Related]
30.
Riabov V; Xu Q; Schmitt N; Streuer A; Ge G; Bolanos L; Wunderlich M; Jann JC; Wein A; Altrock E; Demmerle M; Mukherjee S; Ali AM; Rapp F; Nowak V; Weimer N; Obländer J; Palme I; Göl M; Jawhar A; Darwich A; Wuchter P; Weiss C; Raza A; Foulks JM; Starczynowski DT; Yang FC; Metzgeroth G; Steiner L; Jawhar M; Hofmann WK; Nowak D
Haematologica; 2024 May; 109(5):1426-1438. PubMed ID: 37916386
[TBL] [Abstract][Full Text] [Related]
31. Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation.
You X; Liu F; Binder M; Vedder A; Lasho T; Wen Z; Gao X; Flietner E; Rajagopalan A; Zhou Y; Finke C; Mangaonkar A; Liao R; Kong G; Ranheim EA; Droin N; Hunter AM; Nikolaev S; Balasis M; Abdel-Wahab O; Levine RL; Will B; Nadiminti KVG; Yang D; Geissler K; Solary E; Xu W; Padron E; Patnaik MM; Zhang J
Blood; 2022 Feb; 139(7):1066-1079. PubMed ID: 34699595
[TBL] [Abstract][Full Text] [Related]
32. Prognostic impact of ASXL1 mutations in patients with myelodysplastic syndromes and multilineage dysplasia with or without ring sideroblasts.
Mangaonkar AA; Gangat N; Al-Kali A; Elliott MA; Begna KH; Hanson CA; Ketterling RP; Wolanskyj-Spinner AP; Hogan WJ; Litzow MR; Patnaik MM
Leuk Res; 2018 Aug; 71():60-62. PubMed ID: 30015104
[TBL] [Abstract][Full Text] [Related]
33. ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS.
Sallman DA; Komrokji R; Cluzeau T; Vaupel C; Al Ali NH; Lancet J; Hall J; List A; Padron E; Song J
Blood Cancer J; 2017 Nov; 7(12):633. PubMed ID: 29176559
[No Abstract] [Full Text] [Related]
34. A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia.
Bacher U; Haferlach T; Kern W; Haferlach C; Schnittger S
Haematologica; 2007 Jun; 92(6):744-52. PubMed ID: 17550846
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of ASXL1 mutations in acute myeloid leukemia: A meta-analysis.
Lipilkin PV; Kulaeva ED; Mashkina EV
Leuk Res; 2022 Sep; 120():106910. PubMed ID: 35785697
[TBL] [Abstract][Full Text] [Related]
36. Truncation mutants of ASXL1 observed in myeloid malignancies are expressed at detectable protein levels.
Inoue D; Matsumoto M; Nagase R; Saika M; Fujino T; Nakayama KI; Kitamura T
Exp Hematol; 2016 Mar; 44(3):172-6.e1. PubMed ID: 26700326
[TBL] [Abstract][Full Text] [Related]
37. [Analysis of ASXL1 gene variant in patients with myelodysplastic syndrome].
Chen M; Liu J; Chao H; Qin W; Jiang N; Lu X; Cen L; Jiang Y; Cai X; Zhang R; Wang Q
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2020 Feb; 37(2):110-115. PubMed ID: 32034733
[TBL] [Abstract][Full Text] [Related]
38. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations.
Meggendorfer M; Bacher U; Alpermann T; Haferlach C; Kern W; Gambacorti-Passerini C; Haferlach T; Schnittger S
Leukemia; 2013 Sep; 27(9):1852-60. PubMed ID: 23628959
[TBL] [Abstract][Full Text] [Related]
39. Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia.
Boultwood J; Perry J; Pellagatti A; Fernandez-Mercado M; Fernandez-Santamaria C; Calasanz MJ; Larrayoz MJ; Garcia-Delgado M; Giagounidis A; Malcovati L; Della Porta MG; Jädersten M; Killick S; Hellström-Lindberg E; Cazzola M; Wainscoat JS
Leukemia; 2010 May; 24(5):1062-5. PubMed ID: 20182461
[No Abstract] [Full Text] [Related]
40. The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes.
Duncavage EJ; Tandon B
Int J Lab Hematol; 2015 May; 37 Suppl 1():115-21. PubMed ID: 25976969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
